

# MicroRNA panel provides a more precise lung cancer diagnosis

September 29 2010

---

A test based on a panel of microRNAs under development by Rosetta Genomics, Ltd., in Rehovot, Israel, may allow for more precise diagnosis and better targeted therapy for patients with lung cancer.

Tina B. Edmonston, M.D., director of the clinical laboratory at Rosetta Genomics, Inc., presented data on the assay at the Fourth AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development, held here.

Lung cancers are traditionally divided into two main groups, either neuroendocrine or non-small cell [lung cancer](#). In 20 to 30 percent of the cases it is difficult to make a definitive diagnosis of the tumor subtype using fine needle biopsy.

"Subclassification has become very important in the determination of patient management," said Edmonston. "This subclassification leads to treatment decisions, so it is very important to make the [diagnosis](#) accurately."

Using their proprietary assay, which is still under development, Edmonston and colleagues were able to further subclassify non-small cell lung cancer into squamous and non-squamous, and neuroendocrine into small cell lung cancer and carcinoid with a high level of sensitivity and specificity.

Edmonston said this assay would result in better treatment decisions

because not all subtypes of lung cancer will respond to certain drugs and some may even pose unique risks.

Provided by American Association for Cancer Research

Citation: MicroRNA panel provides a more precise lung cancer diagnosis (2010, September 29)  
retrieved 19 April 2024 from

<https://medicalxpress.com/news/2010-09-microrna-panel-precise-lung-cancer.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.